Barclays PLC Buys 8,713 Shares of Zynex, Inc. (NASDAQ:ZYXI)

Barclays PLC raised its stake in shares of Zynex, Inc. (NASDAQ:ZYXI) by 43.3% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 28,821 shares of the company’s stock after purchasing an additional 8,713 shares during the quarter. Barclays PLC’s holdings in Zynex were worth $236,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in the stock. Hotchkis & Wiley Capital Management LLC increased its stake in Zynex by 24.7% during the third quarter. Hotchkis & Wiley Capital Management LLC now owns 746,380 shares of the company’s stock valued at $6,090,000 after acquiring an additional 147,770 shares during the period. Millennium Management LLC grew its holdings in shares of Zynex by 66.5% during the 2nd quarter. Millennium Management LLC now owns 297,082 shares of the company’s stock worth $2,769,000 after purchasing an additional 118,615 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Zynex by 68.7% during the second quarter. Renaissance Technologies LLC now owns 189,762 shares of the company’s stock valued at $1,769,000 after purchasing an additional 77,300 shares during the period. GSA Capital Partners LLP raised its stake in shares of Zynex by 72.7% in the third quarter. GSA Capital Partners LLP now owns 79,930 shares of the company’s stock valued at $652,000 after purchasing an additional 33,649 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in Zynex by 6.7% in the third quarter. Geode Capital Management LLC now owns 425,509 shares of the company’s stock worth $3,473,000 after purchasing an additional 26,774 shares during the period. Institutional investors and hedge funds own 29.68% of the company’s stock.

Insider Activity

In other news, CFO Daniel J. Moorhead sold 10,000 shares of the firm’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $8.59, for a total value of $85,900.00. Following the completion of the sale, the chief financial officer now directly owns 44,878 shares in the company, valued at approximately $385,502.02. This trade represents a 18.22 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Over the last 90 days, insiders sold 44,000 shares of company stock worth $368,040. Insiders own 52.13% of the company’s stock.

Zynex Stock Performance

Shares of NASDAQ:ZYXI opened at $7.68 on Tuesday. The stock has a market capitalization of $244.61 million, a price-to-earnings ratio of 51.20 and a beta of 0.53. The business’s fifty day moving average price is $8.13 and its two-hundred day moving average price is $8.28. Zynex, Inc. has a fifty-two week low of $7.15 and a fifty-two week high of $13.77. The company has a debt-to-equity ratio of 1.66, a current ratio of 3.94 and a quick ratio of 3.15.

Zynex (NASDAQ:ZYXI) last announced its earnings results on Thursday, October 24th. The company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.01. The business had revenue of $49.97 million during the quarter, compared to analysts’ expectations of $50.83 million. Zynex had a net margin of 2.49% and a return on equity of 13.05%. The firm’s revenue for the quarter was up .1% on a year-over-year basis. During the same quarter last year, the company posted $0.10 EPS. As a group, analysts predict that Zynex, Inc. will post 0.2 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on ZYXI. HC Wainwright reissued a “buy” rating and issued a $17.00 price target on shares of Zynex in a report on Friday, December 6th. Royal Bank of Canada dropped their price target on shares of Zynex from $12.00 to $11.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th.

Zynex Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.